Table 4

Individual responses of total IgG or IgG subclasses after influenza and pneumococcal polysaccharide immunization

Patients

Total IgG

IgG1

IgG2

IgG3

IgG4

Total IgG

IgG1

IgG2

IgG3

IgG4

Previous RTX


Influenza

P23


Pre-RTX

1

176

289

99

125

117

152

95

105

110

115

1

2 a

94

86

98

89

74

102

454

534

203

117

no

3 a

163

128

110

112

111

204

262

107

95

115

no

4 a

154

292

198

178

108

335

77

167

129

148

no

5 a

132

368

99

121

123

217

246

458

128

113

no


Post-RTX

1a

139

202

123

116

153

151

83

85

95

102

no

2

126

260

133

136

158

110

103

104

95

101

2

3

109

93

115

110

107

107

143

105

107

116

no

4

100

97

89

102

91

102

104

98

111

112

no

5a

115

89

72

100

96

93

87

211

112

108

no

6a

85

93

76

87

102

88

82

187

96

107

3

7

98

82

94

96

97

107

95

94

98

94

no

8

103

99

86

124

113

95

233

257

126

117

no

9a

104

102

115

91

103

126

92

105

92

98

1

10

127

222

115

160

170

104

159

248

175

206

2

11a

134

157

110

119

109

122

167

140

125

144

no


Controls

1

117

95

84

113

108

213

91

171

89

83

no

2a

191

252

96

125

127

115

897

521

235

278

no

3

100

157

100

50

105

139

137

178

109

95

no

4

96

145

97

105

113

136

467

216

159

137

no

5

121

205

101

191

126

105

114

112

107

111

no

6

116

124

123

108

119

97

154

136

151

112

no

7

113

123

179

111

111

71

316

259

120

122

no

8

174

234

127

146

121

161

167

140

108

105

no

9

97

98

72

144

123

111

65

84

114

101

no

10

99

142

116

129

124

194

271

122

132

889

no


aPrednisolone, 2.5-10 mg/day.

Controls, RA patients never treated with RTX; P23, pneumococcal polysaccharide vaccine 23; pre-RTX group, RA patients treated with RTX 6 days after vaccination; post-RTX group, RA patients treated with RTX 6 months before vaccination; RTX, rituximab.

The levels of vaccine-specific antibodies at day 0 were taken as 100%. On day 21, the mean increase of antibody levels in the control group was 110%. This value indicated the cutoff for vaccination response in the RTX-treated patients.

Bold numbers and gray boxes indicate levels equal to or greater than the cutoff level (110%).

Rehnberg et al. Arthritis Research & Therapy 2010 12:R111   doi:10.1186/ar3047

Open Data